首页> 外文OA文献 >Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics

【2h】

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics

机译：是前列腺癌是否成为现实的放射性配体疗法的视觉？ III阶段视力审判概述及其对Theranostics未来的重要性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Kambiz Rahbar; Lisa Bodei; Michael J. Morris;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics [J] . Rahbar Kambiz, Bodei Lisa, Morris Michael J. The Journal of Nuclear Medicine . 2019,第11期

机译：是前列腺癌是否成为现实的放射性和治疗的视觉？ III阶段视觉审判概述及其对Theranostics未来的重要性
2. Re: A Phase III Trial to Investigate the Timing of Radiotherapy for Prostate Cancer with High-Risk Features: Background and Rationale of the Radiotherapy-Adjuvant versus Early Salvage (RAVES) Trial [J] . Taneja Samir S. The Journal of Urology . 2015,第2期

机译：RE：III期试验，以研究具有高风险特征的前列腺癌的放疗时间：放射治疗 - 佐剂的背景和理由与早期打捞（Raves）试验
3. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH, Division of Hematology and M [J] . Carroll PR Urologic oncology . 2004,第6期

机译：钇90标记的抗前列腺特异性膜抗原单克隆抗体J591的I期试验，用于雄激素非依赖性前列腺癌Milowsky MI，Nanus DM，Kostakoglu L，Vallabhajosula S，Goldsmith SJ，Bander NH，血液学和M科
4. OVERVIEW OF REVISIONS TO THE ASME BOILER AND PRESSURE VESSEL CODE SECTION VIII DIVISION 3 FOR THE 2019 EDITION AND NEAR FUTURE [C] . Adam P. Maslowski, Daniel Peters, Gregory Mital, ASME Pressure Vessels Piping Conference;High-Pressure Technology Student Paper Symposium and Competition;Annual Student Paper Competition Conference;Rudy Scavuzzo Student Paper Symposium;ASME Nondestructive Evaluation, Diagnosis and Prognosis Division . 2019

机译：ASME锅炉和压力容器规范第VIII篇第3节的修订版，适用于2019年版及不久的将来
5. Alpha-methylacyl-CoA racemase: A candidate gene for prostate cancer and advanced distal colorectal adenomas in the prostate, lung, colorectal, and ovarian cancer screening trial. [D] . Daugherty, Sarah. 2007

机译：α-甲基酰基辅酶A消旋酶：在前列腺癌，肺癌，结肠直肠癌和卵巢癌筛查试验中，前列腺癌和晚期远端结肠直肠腺瘤的候选基因。
6. A Phase III trial of 2 Years of Androgen Suppression (AS) and Radiation Therapy (RT) with or without Adjuvant Chemotherapy (CT) for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group (RTOG) Phase III Randomized Trial NRG Oncology RTOG 9902 [O] . Seth A. Rosenthal, Daniel Hunt, A. Oliver Sartor, -1

机译：高危前列腺癌有或没有辅助化疗（CT）的2年雄激素抑制（AS）和放射治疗（RT）的III期试验：放射疗法肿瘤学组（RTOG）的最终结果III期随机试验NRG肿瘤学RTOG 9902
7. LBA18 IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS) [O] . Olivier Cussenot, Raphaele Renard Penna, Eva Comperat, 2018

机译：LBA18瞬态抗剥夺治疗（ADT）对Leuprorelin LP 11.25mg对惰性前列腺癌（PC）的组织学进展的影响 - III期试验的第III期试验（AS）对Leuprorelin的影响（ADT）的影响LP 11.25 mg关于惰性前列腺癌（PC）的组织学进展（PC） - III期试验的结果与主动监测（AS）
8. Trials of Anti-PSMA Designer T Cells in Advanced Prostate Cancer (Phase 1). Revision [R] . Junghans, R. P. 2007

机译：高级前列腺癌中抗psma Designer T细胞的试验（第1阶段）。调整

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics

著录项

相似文献

相关主题

期刊订阅